Acknowledgment and Consent for Disclosure of
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act
And 18 U.S.C. §208
Particular Matter Waiver

Name of Participant: John Modlin, M.D.

Committee: Vaccines and Related Biological Products Advisory Committee

Meeting Date: February 20-21, 2008

I acknowledge that contingent upon public disclosure of the following financial interest submitted on my FDA Form 3410 and related to the agenda items: the safety and efficacy of a rotavirus manufactured by GlaxoSmithKline, the 2008 – 2009 influenza virus vaccine strain selection, and influenza vaccines for pre-pandemic uses, I am eligible to receive a particular matter waiver under Section 712(c)(2)(B) and 18 U.S.C. §208.

Type of Interest	Nature	Magnitude
Consulting (unrelated)	Competing Firm	Less than $10,000
Consulting (unrelated)	Affected Firm	Less than $10,000

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading this acknowledgement into the record. I understand that without public disclosure of the interests the waiver is not valid.

/s/
John Modlin, M.D.

1/10/08
Date